Tag:
Optimer Pharmaceuticals
Latest Headlines
Latest Headlines
Optimer ousts chairman, top execs over a grant of shares in affiliate
Hank McKinnell has a new biopharma mess to sort out.
Optimer inks $90M C. difficile drug pact with Astellas
Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.
Cubist might stay clear of Ph3 for antibiotic, analyst says
While Cubist Pharmaceuticals ( $CBST ) is mulling over whether to advance its antibiotic against C. difficile infections into late-stage development, an analyst says the developer might not pursue the
Will hospitals pay premium for Optimer's Dificid?
Will hospitals pay more for Optimer Pharmaceuticals' new antibiotic Dificid? That's the question, now that the FDA has given its blessing to the drug, which is the first new treatment in 25 years for
UPDATED: FDA gives Optimer key antibiotic approval
There's going to be a lot of backslapping at barbeques in San Diego this weekend. The FDA sent out word this afternoon that it's approved San Diego-based Optimer Pharmaceuticals' ($OPTR) antibiotic
Stage set for Optimer's weapon against deadly infections
As we put this edition of FierceBiotech to bed, there was still no word from the FDA on potential approval of Optimer Pharmaceuticals' antibiotic fidaxomicin (Dificid). The PDUFA date of May 30 falls
Biotechs pick up slack in antibiotics development
While Big Pharma still has a strong foothold in the antibiotics market, smaller biotechs have tackled the job of replenishing our arsenal of new weapons against infections--especially so-called
Optimer readies antibiotic campaign after winning FDA panel vote
Optimer Pharmaceuticals won the unanimous support of an FDA panel of experts for its new antibiotic fidaxomicin and can now march into the agency with a solid endorsement on safety and efficacy. But
FDA panel readies pivotal review of Optimer's fidaxomicin
Optimer Pharmaceuticals is going into today's expert panel meeting on the antibiotic fidaxomicin armed with some positive remarks from regulators and high hopes for what could become its first
Ahead of panel, FDA staffers back Optimer's antibiotic fidaxomicin
In advance of Tuesday's expert panel review, FDA staffers say they agree with Optimer Pharmaceutical's results from two late-stage studies of its experimental antibiotic. The drug, called
